Mavyret

Product NDC

0074-2625

11-digit product format

000742625

Labeler code

0074

Product ID

0074-2625_2c392930-500d-4e9b-93ac-317c4d48251c

Type

HUMAN PRESCRIPTION DRUG

Nonproprietary name

Glecaprevir and Pibrentasvir

Dosage form

TABLET, FILM COATED

Route

ORAL

Labeler

AbbVie Inc.

Application

NDA209394

Marketing category

NDA

Marketing start

2017-08-03

Substance

GLECAPREVIR; PIBRENTASVIR

Active strength

100; 40 mg/1; mg/1

Pharmacologic classes

Breast Cancer Resistance Protein Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], HCV NS3/4A Protease Inhibitors [MoA], Hepatitis C Virus NS3/4A Protease Inhibitor [EPC], Hepatitis C Virus NS5A Inhibitor [EPC], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], UGT1A1 Inhibitors [MoA], UGT1A1 Inhibitors [MoA]

NDC exclude flag

No

Listing certified through

2027-12-31

Current FDA listing

Yes